Together, these findings are consistent with reduced BCL6 levels enhancing paclitaxel activity in the breast cancer cells by promoting a more sustained G1/S phase cell cycle arrest instead of the more transitory G2/M phase cell cycle arrest observed in the shRNA scramble control cells. This evidence concerns the gene BCL6 and breast carcinoma.